EBQ:TOPCOAT Trial: Difference between revisions
Ostermayer (talk | contribs) |
Ostermayer (talk | contribs) No edit summary |
||
| Line 12: | Line 12: | ||
| pmid= 24484241 | | pmid= 24484241 | ||
| fulltexturl= | | fulltexturl= | ||
| pdfurl= | | pdfurl=http://theddx.org/papers/TOPCOAT.pdf | ||
}} | }} | ||
==Clinical Question== | ==Clinical Question== | ||
Revision as of 19:05, 7 September 2014
incomplete Journal Club Article
Kline J. et al.. "Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial.". J Thromb Haemost. 2014. 12(4):459-468.
PubMed PDF
PubMed PDF
Clinical Question
Does thrombolysis of submissive PE with tenecteplase increases the probability of a favorable composite outcome of death, circulatory shock, intubation, major bleeding in 5 days, recurrent PE, functional capacity or a Physical component summary at 90 day followup.